US20140037774A1 - Composition comprising thylakoids for delaying the uptake of molecules - Google Patents
Composition comprising thylakoids for delaying the uptake of molecules Download PDFInfo
- Publication number
- US20140037774A1 US20140037774A1 US14/001,280 US201214001280A US2014037774A1 US 20140037774 A1 US20140037774 A1 US 20140037774A1 US 201214001280 A US201214001280 A US 201214001280A US 2014037774 A1 US2014037774 A1 US 2014037774A1
- Authority
- US
- United States
- Prior art keywords
- composition
- thylakoids
- glucose
- mammal
- canceled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000002377 thylakoid Anatomy 0.000 title claims abstract description 95
- 239000000203 mixture Substances 0.000 title claims abstract description 86
- 241000124008 Mammalia Species 0.000 claims abstract description 22
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 13
- 210000004347 intestinal mucosa Anatomy 0.000 claims abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 43
- 239000008103 glucose Substances 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 32
- 239000008280 blood Substances 0.000 claims description 30
- 210000004369 blood Anatomy 0.000 claims description 30
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 claims description 26
- 239000002417 nutraceutical Substances 0.000 claims description 26
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 26
- 229930002875 chlorophyll Natural products 0.000 claims description 24
- 235000019804 chlorophyll Nutrition 0.000 claims description 24
- 201000001421 hyperglycemia Diseases 0.000 claims description 19
- 241000195628 Chlorophyta Species 0.000 claims description 8
- 235000009337 Spinacia oleracea Nutrition 0.000 claims description 7
- 230000033228 biological regulation Effects 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 239000007764 o/w emulsion Substances 0.000 claims description 6
- 230000004153 glucose metabolism Effects 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 230000003111 delayed effect Effects 0.000 claims description 3
- 230000002641 glycemic effect Effects 0.000 claims description 3
- 241000219315 Spinacia Species 0.000 claims 3
- 230000001934 delay Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 12
- 210000004877 mucosa Anatomy 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000012141 concentrate Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 8
- 210000000936 intestine Anatomy 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- 108010058846 Ovalbumin Proteins 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 229940092253 ovalbumin Drugs 0.000 description 6
- 208000020401 Depressive disease Diseases 0.000 description 5
- 229920002307 Dextran Polymers 0.000 description 5
- 201000003102 mental depression Diseases 0.000 description 5
- 201000000980 schizophrenia Diseases 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 244000300264 Spinacia oleracea Species 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000004190 glucose uptake Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000000291 postprandial effect Effects 0.000 description 4
- 230000036962 time dependent Effects 0.000 description 4
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000000243 photosynthetic effect Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 208000001280 Prediabetic State Diseases 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229930002868 chlorophyll a Natural products 0.000 description 2
- 229930002869 chlorophyll b Natural products 0.000 description 2
- NSMUHPMZFPKNMZ-VBYMZDBQSA-M chlorophyll b Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C=O)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 NSMUHPMZFPKNMZ-VBYMZDBQSA-M 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- YKXCWZVUWWQSAV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O YKXCWZVUWWQSAV-BTVCFUMJSA-N 0.000 description 1
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical compound O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 description 1
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 241000219305 Atriplex Species 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000219312 Chenopodium Species 0.000 description 1
- 240000006162 Chenopodium quinoa Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000021534 Mangelwurzel Nutrition 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 108700043492 SprD Proteins 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 240000001949 Taraxacum officinale Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 239000007978 cacodylate buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- -1 mono- Chemical class 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A23L1/3002—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to use of composition for regulating the concentration in blood of various molecules by affecting their uptake in the gastro-intestinal system of a mammal. Further, the present invention relates to a method of reducing the transport of molecules through the intestinal mucosa of the intestinal tract of a mammal.
- Hyperglycaemia is a major symptom in objects suffering from non-insulin dependent diabetes, the most prevalent disease affecting individuals with a Westernized life style (Yoon K H, Lee J H, Kim J W, Cho J H et al, Lancet 368: 1681-1688, 2006). Hyperglycaemia is further associated with coronary heart disease, obesity and chronic inflammation (Sinnaeve P R, Steg P G, Fox K A, et al. Archives Internal Medicine 169:402-409, 2009; Shoelson S E, Goldfine A B, Nature Medicine, 15: 373-374, 2009). In affected patients, elevated postprandial glucose is an early indicator of glucose intolerance or a pre-diabetes condition.
- the elevated postprandial glucose level is a more sensitive indicator of pre-diabetes than elevated fasting glucose levels. Treating patients who have early signs of hyperglycaemia, including elevated postprandial glucose level, with intensive glucose control is therefore fundamental to prevent or reduce later cardiovascular morbidity and mortality.
- Other diseases affected by hyperglycaemia include genetic diseases such as schizophrenia and mental depression. These are triggered by production of advanced glycation end products following the reaction between elevated blood glucose levels and intrinsic proteins (Bengmark S, Journal of Parenteral and Enteral Nutrition, 31: 430-440, 2007).
- a reduction of blood glucose levels is thus a desired aim.
- Management of hyperglycaemia disclosed in the art typically relies on:
- glucose is taken up through the apical brush border membrane of the epithelial intestinal cells, mainly by the sodium-glucose linked transporter (SGLT1), to the enterocyte (Dyer J, Wood I S, Palejwala A et al Am J Physiol Gastrointest Liver Physiol 282: G241-248, 2002).
- SGLT1 sodium-glucose linked transporter
- Control of the intestinal absorption of glucose would thus be of help to regulate levels of glucose in the blood. Accordingly, compositions affecting the intestinal absorption of glucose would be of interest.
- the present invention seeks to mitigate, alleviate, eliminate or circumvent conditions associated with hyperglycaemia by providing a composition comprising thylakoids or parts thereof, for reducing the transport of molecules through the intestinal mucosa of the intestinal tract of a mammal and thereby delaying the uptake of molecules, such as saccharides, such as mono-, oligo- or polysaccaride, or proteins, or a mixture thereof, from the gastrointestinal tract, wherein said composition is to be administered to the intestinal tract of a mammal.
- Thylakoids are the photosynthetic membranes present in green leaves and green algae.
- the molecule is glucose
- the present invention seeks to regulate the concentration of such molecules in blood by delaying their uptake, thereby preventing the development of their elevated postprandial concentration, for example reducing hyperglycemia.
- Another aspect of the invention relates to the use of a composition comprising thylakoids or parts thereof, for delaying gastrointestinal uptake of molecules, such as glucose, and thereby reducing the peak of their concentration in blood.
- a composition comprising thylakoids or parts thereof, for delaying gastrointestinal uptake of molecules, such as glucose, and thereby reducing the peak of their concentration in blood.
- the thylakoids are enriched from green leaves or green algae.
- the composition may be provided so that the dose of thylakoids is 2.4 mg to 24 mg thylakoids per kg body mass of the mammal.
- the composition may be an oral pharmaceutical or nutraceutical composition comprising a physiologically tolerable oil-in-water emulsion comprising thylakoids.
- the pharmaceutical or nutraceutical composition comprises 25% (weight) thylakoids.
- the thylakoid composition utilized in the neutraceutical or pharmaceutical is a thylakoid concentrate.
- the tylakoid concentrate contains concentrated thylakoid membranes. Suitable methods for preparing such concentrates are described in WO2010008333, which is incorporated by reference herein in its entirety.
- the thylakoid composition, preferably a concentrate, utilized in the pharmaceutical or nutraceutical composition is characterized in having a chlorophyll a/b ratio of from about 2.0 to 4.0, preferably about 2.6 to 3.4, and most preferably about 2.9 to 3.4.
- the thylakoid composition preferably a concentrate, utilized in the pharmaceutical or nutraceutical composition is characterized in having a protein:chlorophyll ratio of from about 3.0 to about 10.0, preferably about 2.0 to 5.0, 3.0 to 5.0, or 6.0 to 8.0.
- the pharmaceutical or nutraceutical composition is characterized in having from about 8 to about 80 mg chlorophyll content per gram (dry weight, water content less than 6% (weight)), preferably from about 10 to about 50 mg, preferably about 10 mg to 30 mg, 20 mg to 40 mg, or 30 mg to 40 mg chlorophyll content per gram (dry weight).
- the pharmaceutical or nutraceutical composition is characterized in having from about 5 to about 50 g carbohydrate content per 100 g (dry weight, water content less than 6% (weight)), preferably about 10 g to 40 g per 100 g, preferably 15 g to 30 g, 20 g to 30 g or 30 g to 40 g per 100 g (dry weight),In some embodiments, the pharmaceutical or nutraceutical composition is characterized in having from about 10 to about 60 g protein content per 100 g (dry weight, water content less than 6% (weight)), preferably about 10 g to 40 g per 100 g, preferably 15 g to 30 g, 20 g to 30 g or 30 g to 40 g per 100 g (dry weight).
- the pharmaceutical or nutraceutical composition further comprises 25% (weight) oil.
- the pharmaceutical or nutraceutical composition may be used in treatment by oral administration of a condition related to blood glucose levels.
- the pharmaceutical or nutraceutical composition may also be used to enhance glucose metabolism, to improve blood glucose regulation, to improve pancreatic health, to lower appetite or to decrease body weight in a subject.
- a further aspect of the invention relates to a composition
- a composition comprising thylakoids, or parts thereof, for delaying the uptake of molecules, such as proteins, eg. ovalbumin, amino acids, peptides, oligosaccharide or polysaccharide, eg. dextran, in the intestinal tract of mammal.
- molecules such as proteins, eg. ovalbumin, amino acids, peptides, oligosaccharide or polysaccharide, eg. dextran
- the thylakoids are enriched from green leaves, such as spinach, or green algae.
- the composition may be provided so that the dose of thylakoids is 2.4 mg to 24 mg thylakoids per kg body mass of the mammal.
- the composition is administered orally.
- the composition may preferably be a part of a foodstuff or a medicament.
- the composition may be an oral pharmaceutical or nutraceutical composition comprising a physiologically tolerable oil-in-water emulsion comprising thylakoids.
- the pharmaceutical or nutraceutical composition comprises 25% (weight) thylakoids.
- the thylakoid composition utilized in the neutraceutical or pharmaceutical is a thylakoid concentrate.
- the thylakoid concentrate contains concentrated thylakoid membranes. Suitable methods for preparing such concentrates are described in WO2010008333, which is incorporated by reference herein in its entirety.
- the thylakoid composition, preferably a concentrate, utilized in the pharmaceutical or nutraceutical composition is characterized in having a chlorophyll a/b ratio of from about 2.0 to 4.0, preferably about 2.6 to 3.4, and most preferably about 2.9 to 3.4.
- the thylakoid composition preferably a concentrate, utilized in the pharmaceutical or nutraceutical composition is characterized in having a protein:chlorophyll ratio (w/w) of from about 3.0 to about 10.0, preferably about 2.0 to 5.0, 3.0 to 5.0, or 6.0 to 8.0.
- the pharmaceutical or nutraceutical composition is characterized in having from about 8 to about 80 mg chlorophyll content per gram (dry weight, water content less than 6% (weight)), preferably from about 10 to about 50 mg, preferably about 10 mg to 30 mg, 20 mg to 40 mg, or 30 mg to 40 mg chlorophyll content per gram (dry weight).
- the pharmaceutical or nutraceutical composition is characterized in having from about 5 to about 50 g carbohydrate content per 100 g (dry weight, water content less than 6% (weight)), preferably about 10 g to 40 g per 100 g, preferably 15 g to 30 g, 20 g to 30 g or 30 g to 40 g per 100 g (dry weight).
- the pharmaceutical or nutraceutical composition is characterized in having from about 10 to about 60 g protein content per 100 g (dry weight, water content less than 6% (weight)), preferably about 10 g to 40 g per 100 g, preferably 15 g to 30 g, 20 g to 30 g or 30 g to 40 g per 100 g (dry weight).
- the pharmaceutical or nutraceutical composition further comprises 25% (weight) oil.
- the pharmaceutical or nutraceutical composition may be used in treatment by oral administration of a condition related to blood glucose levels.
- the pharmaceutical or nutraceutical composition may also be used to enhance glucose metabolism, to improve blood glucose regulation, to improve pancreatic health, to lower appetite or to decrease body weight in a subject.
- a further aspect of the invention relates to non-therapeutic use of a composition comprising thylakoids, or parts thereof, for reducing the transport of molecules through the intestinal mucosa of the intestinal tract of a mammal.
- a further aspect of the invention relates to use of a composition comprising thylakoids, or parts thereof, for reducing glycemic index of foodstuff.
- a further aspect of the invention relates to method of treatment of a condition in a mammalian subject by oral administration to said subject of an effective amount of a composition according embodiments of the invention.
- the condition may be hyperglycemia, such as postprandial hyperglycemia, or a disease or a disorder associated with hyperglycemia, such as diabetes mellitus, schizophrenia and mental depression.
- hyperglycemia such as postprandial hyperglycemia
- a disease or a disorder associated with hyperglycemia such as diabetes mellitus, schizophrenia and mental depression.
- FIGS. 1 to 3 depict the effect of thylakoids on the time dependent passage of molecules through the rat (using the technique of the Ussing chamber (3, 4)). Especially,
- FIG. 1 shows the time dependent passage of 3H-methyl-glucose through the rat mucosa in the absence of thylakoids (control) and in the absence of increasing concentration of thylakoids (1.2, 2.9, and 5.8 mg chlorophyll/ml),
- FIG. 2 shows the time dependent passage of FITC-D4-dextran through the rat mucosa in the absence of thylakoids (control) and in the presence of increasing concentration of thylakoids (0.6, 1.2, 2.9, 5.8, and 8.7 mg chlorophyll/ml), and
- FIG. 3 shows the time dependent passage of ovalbumin through the rat mucosa in the absence of thylakoids (control) and in the presence of increasing concentrations of thylakoids (0.6, 1.2, 2.9, 5.8, and 8.7 mg chlorophyll/ml).
- FIG. 4 depicts an electron microscopy photography of thylakoids (arrows) attached to the mucosa layer of rat intestine.
- FIG. 5 depicts the concentration of blood glucose in rats after oral intake of glucose alone (small tilted squares) and after oral intake of glucose together with thylakoids (large squares).
- the present inventors have found that oral administration of a composition comprising thylakoids, or parts thereof, to a mammal reduces the glucose uptake in the intestine of the mammal.
- Thylakoids are digested by the body, why they can be used without any toxic effects. However, thylakoids are digested more slowly than other cell compartments, such as mitochondria, which is beneficial.
- compositions may be used for the prevention and/or treatment of hyperglycemia, and especially postprandial hyperglycemia. Further, by reducing the glucose uptake in the intestine, the blood glucose levels may be lowered. By lowering the blood glucose levels insulin resistance, diabetes, cardiovascular disease, and inflammation may be prevented and/or treated. Further, conditions with a strong inflammatory component, such as mental depression and schizophrenia, may be greatly improved.
- the present invention relates to the use of thylakoids, i.e. photosynthetic membranes from green leaves or green algae, or parts thereof, for the reduction of the transport of molecules, such as glucose, through the intestinal mucosa of the intestine.
- thylakoids i.e. photosynthetic membranes from green leaves or green algae, or parts thereof
- the thylakoids, or parts thereof, used may be part of a pharmaceutical as well as a food composition.
- An embodiment relates to the use of a composition comprising thylakoids, or parts thereof, for preventing and/or treating hyperglycemia and especially postprandial hyperglycemia.
- the compositions are used to promote healthy blood sugar (e.g., glucose) levels, to manage blood sugar levels, to support healthy blood sugar regulation and/or balance, to reduce tendency to insulin resistance, and combinations thereof.
- healthy blood sugar e.g., glucose
- An embodiment relates to the use of a composition comprising thylakoids, or parts thereof, for preventing and/or treating a disease or a disorder associated with hyperglycemia, such as diabetes mellitus, schizophrenia and mental depression.
- a disease or a disorder associated with hyperglycemia such as diabetes mellitus, schizophrenia and mental depression.
- said disease or a disorder associated with hyperglycemia may be diabetes mellitus.
- an embodiment relates to the use of a composition comprising thylakoids, or parts thereof, for delaying the glucose uptake in the intestine of a mammal.
- Said thylakoids may origin from leaves of any photosynthesizing plants such as clover, rape, sugar beet, dandelion, Arabidopsis thaliana , maize, tobacco, sun flower, salad, Chenopodium, Atriplex, spinach, mangold, quinoa, kale and grasses or a mixture thereof.
- the thylakoids originate from leaves of spinach.
- the composition may be used for oral administration. Further, it may be part of a foodstuff or a medicament.
- Thylakoids are the photosynthetic membranes of green leaves or green algae and they are responsible for the light reaction of photosynthesis.
- the preparation of a composition comprising thylakoids, or parts thereof, may be carried out in many different ways, as has been described in the literature (cf. Andreasson et al., Emek et al., and WO 2006/7132586 A1, incorporated herein by reference in its entirety).
- the composition comprises thylakoids, or parts thereof, isolated or at least enriched from green leaves or green algae.
- thylakoids may be included in foodstuff in many different ways since they are themselves food and they can also be included in different types of pharmaceutical formula as previously described in WO 2006/7132586 A1.
- Thylakoid membranes were prepared by isolation from spinach leaves according to Andreasson et al. (1).
- the concentration of thylakoids was expressed as mg chlorophyll/ml (Chl/ml) and determined by the method of Porra (cf. reference (2)) 1 mg chlorophyll corresponds to about 12 mg thylakoids (5).
- the intestine was cut in 3 cm sections, opened along the mesentery and pinched to the nails of the pre-heated (37° C.) Ussing half-cell (Precision Instrument Design, Los Altos, Calif., USA), modified in accordance with Grass and Sweetana (4).
- the half-cell was connected to another half-cell, and thus the arrangement had two sides: one facing the mucosal side of the intestine and the other facing the serosal side, with an exposed intestinal area of 1 ⁇ 78 cm2.
- the Ussing chambers were filled with 5 ml Krebs buffer, kept at 37° C. and connected to a carbogen supply. All intestinal segments were mounted in the chambers within 30 minutes after the intestine was collected. The intestinal segments were considered viable for a minimum of two hours after mounted in the chambers (6).
- the buffer was exchanged to fresh buffer in the serosal half-cell, and test solution in the mucosal half-cell.
- the test solution (5 ml) consisted of modified Krebs buffer supplemented with oleic acid (18:1n-9, 5.07 mM), NaTDC (5.2 g/l), and the marker molecules methyl-D glucose, 3-O-methyl 3H (190 Da, 1.85′10-2 GBq, 3.1 ⁇ l/ml,) or methyl-D glucose, 3-O-methyl 14C (190 Da, 1.85′10-3 GBq, 0.8 ⁇ l/ml), FITC-dextran (4 000 Da, 1 g/l) and ovalbumin (45 000 Da, 25 g/l).
- Thylakoid membranes both non-treated and treated with trypsin—were also added to the test solution to get final concentrations of 1.2, 2.9 and 5.8 chl mg/ml.
- This concentration interval is obtainable by dosing from about 0.2 mg to about 2 mg chlorophyll per kg body mass of the subject to be treated, which corresponds to about 2.4 mg to about 24 mg isolated thylakoids per kg body mass of the subject to be treated. Serosal samples of 1 ml were collected every 20 minutes during 120 minutes, with replacement of the sampled volume by fresh buffer.
- the abovementioned dosage is for a composition with a high purity of thylakoids, i.e. isolated thylakoids.
- the dosing of thylakoids is equivalent to from about 1.0 mg to about 2.0 mg chlorophyll per kg body mass of the subject to be treated, preferably from about 1.5 to about 2.0 mg chlorophyll per kg body mass of the subject to be treated.
- the thylakoids are not isolated, but only concentrated to a suitable level, such as characterized in having from about 8 to about 80 mg chlorophyll content per gram (dry weight, water content less than 6% (weight)) composition, preferably from about 10 to about 50 mg, preferably about 10 mg to 30 mg, 20 mg to 40 mg, or 30 mg to 40 mg chlorophyll content per gram (dry weight) composition.
- the pharmaceutical or nutraceutical composition is characterized in having from about 5 to about 50 g carbohydrate content per 100 g (dry weight, water content less than 6% (weight)), preferably about 10 g to 40 g per 100 g, preferably 15 g to 30 g, 20 g to 30 g or 30 g to 40 g per 100 g (dry weight),In some embodiments, the pharmaceutical or nutraceutical composition is characterized in having from about 10 to about 60 g protein content per 100 g (dry weight, water content less than 6% (weight)), preferably about 10 g to 40 g per 100 g, preferably 15 g to 30 g, 20 g to 30 g or 30 g to 40 g per 100 g (dry weight).
- the thylakoids are concentrated so that the chlorophyll content is from about 8 mg to 80 mg chlorophyll per g composition (dry weight).
- the total daily does of the pharmaceutical or nutraceutical composition is from about 2 g to about 10 g.
- the amount of radio labelled methyl-glucose in 0.5 -ml serosal samples was measured in a beta counter (Scint TriCarb Liquid Scintillation Analyzer 2100TR, Perkin Elmer, Boston, Mass., USA), after mixing the serosal sample with 5 ml liquid scintillation cocktail.
- FITC-dextran was quantified by fluorescence spectrophotometry (CytoFlourTM 2300, Millipore Corporation, Bedford, Mass., USA) at an excitation wavelength of 480 nm and an emission wavelength of 520 nm, where FITC-dextran dissolved in modified Krebs buffer was used as standard. Quantification of ovalbumin was performed by electro immunoassay (20) using a specific antiserum to ovalbumin (A6075) with purified ovalbumin (A-5503) as standard.
- FIGS. 1 to 3 show that thylakoids reduce the passage of all three molecules, representing different types of molecules, monosaccharides, polysaccharide and proteins, through the mucosa in a dose dependent way.
- FIG. 4 shows an electron microscope picture of thylakoids attached to the mucosa layer after an Ussing experiment.
- Thylakoid membranes were prepared as described in EXAMPLE 1. Rats were of the Sprague-Dawley stock (Mole: SPRD Han).
- a rat was fed an emulsion of 2.5 g rapeseed oil in 5 g water (control) and a second rat was fed an emulsion of 2.5 g rapeseed oil in 5 g water plus 2.5 g thylakoids via bolustube. After 2.5 hours both rats were fed each 3 mL 15% glucose solution. Blood glucose was then measured at different times during 2 hours. The results are shown in Table 1 and FIG. 5 . As can be seen there is a significant reduction of the blood glucose over time when thylakoids are co-administered.
- An oil-in-water emulsion is advantageous, since it reduces the rate, with which thylakoids are digested by the body.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed, is a composition comprising thylakoids, or parts thereof, for reducing the transport of molecules through the intestinal mucosa of the intestinal tract of a mammal.
Description
- The present invention relates to use of composition for regulating the concentration in blood of various molecules by affecting their uptake in the gastro-intestinal system of a mammal. Further, the present invention relates to a method of reducing the transport of molecules through the intestinal mucosa of the intestinal tract of a mammal.
- Hyperglycaemia is a major symptom in objects suffering from non-insulin dependent diabetes, the most prevalent disease affecting individuals with a Westernized life style (Yoon K H, Lee J H, Kim J W, Cho J H et al, Lancet 368: 1681-1688, 2006). Hyperglycaemia is further associated with coronary heart disease, obesity and chronic inflammation (Sinnaeve P R, Steg P G, Fox K A, et al. Archives Internal Medicine 169:402-409, 2009; Shoelson S E, Goldfine A B, Nature Medicine, 15: 373-374, 2009). In affected patients, elevated postprandial glucose is an early indicator of glucose intolerance or a pre-diabetes condition. The elevated postprandial glucose level is a more sensitive indicator of pre-diabetes than elevated fasting glucose levels. Treating patients who have early signs of hyperglycaemia, including elevated postprandial glucose level, with intensive glucose control is therefore fundamental to prevent or reduce later cardiovascular morbidity and mortality.
- Other diseases affected by hyperglycaemia include genetic diseases such as schizophrenia and mental depression. These are triggered by production of advanced glycation end products following the reaction between elevated blood glucose levels and intrinsic proteins (Bengmark S, Journal of Parenteral and Enteral Nutrition, 31: 430-440, 2007).
- A reduction of blood glucose levels is thus a desired aim. Management of hyperglycaemia disclosed in the art typically relies on:
-
- reducing the dietary carbohydrate intake;
- replacing the use of high-glycaemic carbohydrates by low-glycaemic carbohydrates; and/or
- using hypoglycaemic agents that stimulate the uptake of glucose from the blood into peripheral cells.
- Medical therapies to reduce hyperglycaemia in patient suffering from
type 2 diabetes mellitus, also known as non-insulin dependent diabetes, typically involve insulin-dependent mechanisms and do thereby lose their effectiveness as pancreatic β-cell function declines (Smiley D, Umpierrez G E, Annals New York Academy. Science 1212: 1-11, 2010). - After digestion of dietary carbohydrates, glucose is taken up through the apical brush border membrane of the epithelial intestinal cells, mainly by the sodium-glucose linked transporter (SGLT1), to the enterocyte (Dyer J, Wood I S, Palejwala A et al Am J Physiol Gastrointest Liver Physiol 282: G241-248, 2002).
- Control of the intestinal absorption of glucose would thus be of help to regulate levels of glucose in the blood. Accordingly, compositions affecting the intestinal absorption of glucose would be of interest.
- It would further be of interest to be able to regulate the uptake of small as well as large molecules, such as saccharides, amino acids, peptides, and proteins, particularly in patients with disturbed intestinal barrier function.
- Consequently, the present invention seeks to mitigate, alleviate, eliminate or circumvent conditions associated with hyperglycaemia by providing a composition comprising thylakoids or parts thereof, for reducing the transport of molecules through the intestinal mucosa of the intestinal tract of a mammal and thereby delaying the uptake of molecules, such as saccharides, such as mono-, oligo- or polysaccaride, or proteins, or a mixture thereof, from the gastrointestinal tract, wherein said composition is to be administered to the intestinal tract of a mammal. Thylakoids are the photosynthetic membranes present in green leaves and green algae.
- In an embodiment, the molecule is glucose.
- Further, the present invention seeks to regulate the concentration of such molecules in blood by delaying their uptake, thereby preventing the development of their elevated postprandial concentration, for example reducing hyperglycemia.
- Another aspect of the invention relates to the use of a composition comprising thylakoids or parts thereof, for delaying gastrointestinal uptake of molecules, such as glucose, and thereby reducing the peak of their concentration in blood. By reducing the intestinal uptake of glucose, development of diabetes and other diseases and disorders related to hyperglycaemia, such as such as diabetes mellitus, schizophrenia and mental depression may be prevented and/or treated.
- In an embodiment, the thylakoids are enriched from green leaves or green algae.
- The composition may be provided so that the dose of thylakoids is 2.4 mg to 24 mg thylakoids per kg body mass of the mammal.
- The composition may be an oral pharmaceutical or nutraceutical composition comprising a physiologically tolerable oil-in-water emulsion comprising thylakoids.
- In an embodiment, the pharmaceutical or nutraceutical composition comprises 25% (weight) thylakoids.
- In some embodiments, the thylakoid composition utilized in the neutraceutical or pharmaceutical is a thylakoid concentrate. In preferred embodiments, the tylakoid concentrate contains concentrated thylakoid membranes. Suitable methods for preparing such concentrates are described in WO2010008333, which is incorporated by reference herein in its entirety. In some embodiments, the thylakoid composition, preferably a concentrate, utilized in the pharmaceutical or nutraceutical composition is characterized in having a chlorophyll a/b ratio of from about 2.0 to 4.0, preferably about 2.6 to 3.4, and most preferably about 2.9 to 3.4. In some embodiments, the thylakoid composition, preferably a concentrate, utilized in the pharmaceutical or nutraceutical composition is characterized in having a protein:chlorophyll ratio of from about 3.0 to about 10.0, preferably about 2.0 to 5.0, 3.0 to 5.0, or 6.0 to 8.0.
- In some embodiments, the pharmaceutical or nutraceutical composition is characterized in having from about 8 to about 80 mg chlorophyll content per gram (dry weight, water content less than 6% (weight)), preferably from about 10 to about 50 mg, preferably about 10 mg to 30 mg, 20 mg to 40 mg, or 30 mg to 40 mg chlorophyll content per gram (dry weight).
- In some embodiments, the pharmaceutical or nutraceutical composition is characterized in having from about 5 to about 50 g carbohydrate content per 100 g (dry weight, water content less than 6% (weight)), preferably about 10 g to 40 g per 100 g, preferably 15 g to 30 g, 20 g to 30 g or 30 g to 40 g per 100 g (dry weight),In some embodiments, the pharmaceutical or nutraceutical composition is characterized in having from about 10 to about 60 g protein content per 100 g (dry weight, water content less than 6% (weight)), preferably about 10 g to 40 g per 100 g, preferably 15 g to 30 g, 20 g to 30 g or 30 g to 40 g per 100 g (dry weight).
- In an embodiment, the pharmaceutical or nutraceutical composition further comprises 25% (weight) oil.
- The pharmaceutical or nutraceutical composition may be used in treatment by oral administration of a condition related to blood glucose levels.
- The pharmaceutical or nutraceutical composition may also be used to enhance glucose metabolism, to improve blood glucose regulation, to improve pancreatic health, to lower appetite or to decrease body weight in a subject.
- A further aspect of the invention relates to a composition comprising thylakoids, or parts thereof, for delaying the uptake of molecules, such as proteins, eg. ovalbumin, amino acids, peptides, oligosaccharide or polysaccharide, eg. dextran, in the intestinal tract of mammal.
- In an embodiment, the thylakoids are enriched from green leaves, such as spinach, or green algae.
- The composition may be provided so that the dose of thylakoids is 2.4 mg to 24 mg thylakoids per kg body mass of the mammal.
- In an embodiment, the composition is administered orally.
- The composition may preferably be a part of a foodstuff or a medicament.
- The composition may be an oral pharmaceutical or nutraceutical composition comprising a physiologically tolerable oil-in-water emulsion comprising thylakoids.
- In an embodiment, the pharmaceutical or nutraceutical composition comprises 25% (weight) thylakoids.
- In some embodiments, the thylakoid composition utilized in the neutraceutical or pharmaceutical is a thylakoid concentrate. In preferred embodiments, the thylakoid concentrate contains concentrated thylakoid membranes. Suitable methods for preparing such concentrates are described in WO2010008333, which is incorporated by reference herein in its entirety. In some embodiments, the thylakoid composition, preferably a concentrate, utilized in the pharmaceutical or nutraceutical composition is characterized in having a chlorophyll a/b ratio of from about 2.0 to 4.0, preferably about 2.6 to 3.4, and most preferably about 2.9 to 3.4. In some embodiments, the thylakoid composition, preferably a concentrate, utilized in the pharmaceutical or nutraceutical composition is characterized in having a protein:chlorophyll ratio (w/w) of from about 3.0 to about 10.0, preferably about 2.0 to 5.0, 3.0 to 5.0, or 6.0 to 8.0.
- In some embodiments, the pharmaceutical or nutraceutical composition is characterized in having from about 8 to about 80 mg chlorophyll content per gram (dry weight, water content less than 6% (weight)), preferably from about 10 to about 50 mg, preferably about 10 mg to 30 mg, 20 mg to 40 mg, or 30 mg to 40 mg chlorophyll content per gram (dry weight).
- In some embodiments, the pharmaceutical or nutraceutical composition is characterized in having from about 5 to about 50 g carbohydrate content per 100 g (dry weight, water content less than 6% (weight)), preferably about 10 g to 40 g per 100 g, preferably 15 g to 30 g, 20 g to 30 g or 30 g to 40 g per 100 g (dry weight).
- In some embodiments, the pharmaceutical or nutraceutical composition is characterized in having from about 10 to about 60 g protein content per 100 g (dry weight, water content less than 6% (weight)), preferably about 10 g to 40 g per 100 g, preferably 15 g to 30 g, 20 g to 30 g or 30 g to 40 g per 100 g (dry weight).
- In an embodiment, the pharmaceutical or nutraceutical composition further comprises 25% (weight) oil.
- The pharmaceutical or nutraceutical composition may be used in treatment by oral administration of a condition related to blood glucose levels.
- The pharmaceutical or nutraceutical composition may also be used to enhance glucose metabolism, to improve blood glucose regulation, to improve pancreatic health, to lower appetite or to decrease body weight in a subject.
- A further aspect of the invention relates to non-therapeutic use of a composition comprising thylakoids, or parts thereof, for reducing the transport of molecules through the intestinal mucosa of the intestinal tract of a mammal.
- A further aspect of the invention relates to use of a composition comprising thylakoids, or parts thereof, for reducing glycemic index of foodstuff.
- A further aspect of the invention relates to method of treatment of a condition in a mammalian subject by oral administration to said subject of an effective amount of a composition according embodiments of the invention.
- The condition may be hyperglycemia, such as postprandial hyperglycemia, or a disease or a disorder associated with hyperglycemia, such as diabetes mellitus, schizophrenia and mental depression.
-
FIGS. 1 to 3 depict the effect of thylakoids on the time dependent passage of molecules through the rat (using the technique of the Ussing chamber (3, 4)). Especially, -
FIG. 1 shows the time dependent passage of 3H-methyl-glucose through the rat mucosa in the absence of thylakoids (control) and in the absence of increasing concentration of thylakoids (1.2, 2.9, and 5.8 mg chlorophyll/ml), -
FIG. 2 shows the time dependent passage of FITC-D4-dextran through the rat mucosa in the absence of thylakoids (control) and in the presence of increasing concentration of thylakoids (0.6, 1.2, 2.9, 5.8, and 8.7 mg chlorophyll/ml), and -
FIG. 3 shows the time dependent passage of ovalbumin through the rat mucosa in the absence of thylakoids (control) and in the presence of increasing concentrations of thylakoids (0.6, 1.2, 2.9, 5.8, and 8.7 mg chlorophyll/ml). -
FIG. 4 depicts an electron microscopy photography of thylakoids (arrows) attached to the mucosa layer of rat intestine. -
FIG. 5 depicts the concentration of blood glucose in rats after oral intake of glucose alone (small tilted squares) and after oral intake of glucose together with thylakoids (large squares). - The present inventors have found that oral administration of a composition comprising thylakoids, or parts thereof, to a mammal reduces the glucose uptake in the intestine of the mammal.
- Thylakoids are digested by the body, why they can be used without any toxic effects. However, thylakoids are digested more slowly than other cell compartments, such as mitochondria, which is beneficial.
- Thus, such compositions may be used for the prevention and/or treatment of hyperglycemia, and especially postprandial hyperglycemia. Further, by reducing the glucose uptake in the intestine, the blood glucose levels may be lowered. By lowering the blood glucose levels insulin resistance, diabetes, cardiovascular disease, and inflammation may be prevented and/or treated. Further, conditions with a strong inflammatory component, such as mental depression and schizophrenia, may be greatly improved.
- Thus, the present invention relates to the use of thylakoids, i.e. photosynthetic membranes from green leaves or green algae, or parts thereof, for the reduction of the transport of molecules, such as glucose, through the intestinal mucosa of the intestine. By reducing the transport of such molecules, the intestinal uptake of molecules is delayed. Thus, diseases caused by unbalanced concentration of the molecules, such as glucose, in the blood may be prevented and/or treated. The thylakoids, or parts thereof, used may be part of a pharmaceutical as well as a food composition.
- An embodiment, relates to the use of a composition comprising thylakoids, or parts thereof, for preventing and/or treating hyperglycemia and especially postprandial hyperglycemia. In some embodiments, the compositions are used to promote healthy blood sugar (e.g., glucose) levels, to manage blood sugar levels, to support healthy blood sugar regulation and/or balance, to reduce tendency to insulin resistance, and combinations thereof.
- An embodiment, relates to the use of a composition comprising thylakoids, or parts thereof, for preventing and/or treating a disease or a disorder associated with hyperglycemia, such as diabetes mellitus, schizophrenia and mental depression. Especially, said disease or a disorder associated with hyperglycemia may be diabetes mellitus.
- Further, an embodiment relates to the use of a composition comprising thylakoids, or parts thereof, for delaying the glucose uptake in the intestine of a mammal.
- Said thylakoids may origin from leaves of any photosynthesizing plants such as clover, rape, sugar beet, dandelion, Arabidopsis thaliana, maize, tobacco, sun flower, salad, Chenopodium, Atriplex, spinach, mangold, quinoa, kale and grasses or a mixture thereof. Preferably, the thylakoids originate from leaves of spinach.
- The composition may be used for oral administration. Further, it may be part of a foodstuff or a medicament.
- Thylakoids are the photosynthetic membranes of green leaves or green algae and they are responsible for the light reaction of photosynthesis. The preparation of a composition comprising thylakoids, or parts thereof, may be carried out in many different ways, as has been described in the literature (cf. Andreasson et al., Emek et al., and WO 2006/7132586 A1, incorporated herein by reference in its entirety). Preferably the composition comprises thylakoids, or parts thereof, isolated or at least enriched from green leaves or green algae.
- Further, thylakoids, or parts thereof, may be included in foodstuff in many different ways since they are themselves food and they can also be included in different types of pharmaceutical formula as previously described in WO 2006/7132586 A1.
- Thylakoid membranes were prepared by isolation from spinach leaves according to Andreasson et al. (1).The concentration of thylakoids was expressed as mg chlorophyll/ml (Chl/ml) and determined by the method of Porra (cf. reference (2)) 1 mg chlorophyll corresponds to about 12 mg thylakoids (5).
- A total of eight female rats (220-280 g) were anaesthetized in the morning with isoflouran whereafter the proximal and distal parts of the small intestine were collected, rinsed and immediately immersed in room-tempered modified Krebs buffer (0×1 M NaCl/3 mM CaCl2/5×5 mM KC1/14 mM KH2PO4/29 mM NaHCO3/5×7 mM Na-pyruvate/7 mM Na-fumarate/5×7 mM Na-glutamate/13×4 mM glucose/pH 7.4) oxygenated with carbogen (95/5%, O2/CO2). The intestine was cut in 3 cm sections, opened along the mesentery and pinched to the nails of the pre-heated (37° C.) Ussing half-cell (Precision Instrument Design, Los Altos, Calif., USA), modified in accordance with Grass and Sweetana (4). The half-cell was connected to another half-cell, and thus the arrangement had two sides: one facing the mucosal side of the intestine and the other facing the serosal side, with an exposed intestinal area of 1×78 cm2. The Ussing chambers were filled with 5 ml Krebs buffer, kept at 37° C. and connected to a carbogen supply. All intestinal segments were mounted in the chambers within 30 minutes after the intestine was collected. The intestinal segments were considered viable for a minimum of two hours after mounted in the chambers (6).
- At start of the experiment, the buffer was exchanged to fresh buffer in the serosal half-cell, and test solution in the mucosal half-cell. The test solution (5 ml) consisted of modified Krebs buffer supplemented with oleic acid (18:1n-9, 5.07 mM), NaTDC (5.2 g/l), and the marker molecules methyl-D glucose, 3-O-methyl 3H (190 Da, 1.85′10-2 GBq, 3.1 μl/ml,) or methyl-D glucose, 3-O-methyl 14C (190 Da, 1.85′10-3 GBq, 0.8 μl/ml), FITC-dextran (4 000 Da, 1 g/l) and ovalbumin (45 000 Da, 25 g/l). Thylakoid membranes—both non-treated and treated with trypsin—were also added to the test solution to get final concentrations of 1.2, 2.9 and 5.8 chl mg/ml. This concentration interval is obtainable by dosing from about 0.2 mg to about 2 mg chlorophyll per kg body mass of the subject to be treated, which corresponds to about 2.4 mg to about 24 mg isolated thylakoids per kg body mass of the subject to be treated. Serosal samples of 1 ml were collected every 20 minutes during 120 minutes, with replacement of the sampled volume by fresh buffer.
- The abovementioned dosage is for a composition with a high purity of thylakoids, i.e. isolated thylakoids.
- In some embodiments, the dosing of thylakoids is equivalent to from about 1.0 mg to about 2.0 mg chlorophyll per kg body mass of the subject to be treated, preferably from about 1.5 to about 2.0 mg chlorophyll per kg body mass of the subject to be treated. This corresponds to about 12 mg to about 24 mg isolated thylakoids per kg body mass of the subject to be treated, preferably from about 18 mg to about 24 mg isolated thylakoids per kg body mass of the subject to be treated.
- In some embodiments, the thylakoids are not isolated, but only concentrated to a suitable level, such as characterized in having from about 8 to about 80 mg chlorophyll content per gram (dry weight, water content less than 6% (weight)) composition, preferably from about 10 to about 50 mg, preferably about 10 mg to 30 mg, 20 mg to 40 mg, or 30 mg to 40 mg chlorophyll content per gram (dry weight) composition.
- In some embodiments, the pharmaceutical or nutraceutical composition is characterized in having from about 5 to about 50 g carbohydrate content per 100 g (dry weight, water content less than 6% (weight)), preferably about 10 g to 40 g per 100 g, preferably 15 g to 30 g, 20 g to 30 g or 30 g to 40 g per 100 g (dry weight),In some embodiments, the pharmaceutical or nutraceutical composition is characterized in having from about 10 to about 60 g protein content per 100 g (dry weight, water content less than 6% (weight)), preferably about 10 g to 40 g per 100 g, preferably 15 g to 30 g, 20 g to 30 g or 30 g to 40 g per 100 g (dry weight).
- In some embodiments, the thylakoids are concentrated so that the chlorophyll content is from about 8 mg to 80 mg chlorophyll per g composition (dry weight).
- In some embodiments, the total daily does of the pharmaceutical or nutraceutical composition is from about 2 g to about 10 g.
- The amount of radio labelled methyl-glucose in 0.5 -ml serosal samples was measured in a beta counter (Scint TriCarb Liquid Scintillation Analyzer 2100TR, Perkin Elmer, Boston, Mass., USA), after mixing the serosal sample with 5 ml liquid scintillation cocktail. FITC-dextran was quantified by fluorescence spectrophotometry (CytoFlour™ 2300, Millipore Corporation, Bedford, Mass., USA) at an excitation wavelength of 480 nm and an emission wavelength of 520 nm, where FITC-dextran dissolved in modified Krebs buffer was used as standard. Quantification of ovalbumin was performed by electro immunoassay (20) using a specific antiserum to ovalbumin (A6075) with purified ovalbumin (A-5503) as standard.
- The results of the using experiments are shown in
FIGS. 1 to 3 . They show that thylakoids reduce the passage of all three molecules, representing different types of molecules, monosaccharides, polysaccharide and proteins, through the mucosa in a dose dependent way. - Following every experiment, a sample from the serosal half-cell was collected and analysed for chlorophyll content to investigate a possible thylakoid migration through the intestinal wall. No such migration was found.
- Intestinal segments incubated for 120 minutes in Ussing chambers in the absence of oleic acid and NaTDC but with thylakoid membranes (2.9 mg chl/ml) were fixed with 2.5% glutaraldehyde in 0.15M cacodylate buffer and embedded in Epon, and finally stained in 3% (v/v) uranyl acetate and lead citrate.
FIG. 4 shows an electron microscope picture of thylakoids attached to the mucosa layer after an Ussing experiment. - Without being bound to any theory, it is believed that the retardation of the passage of molecules through the mucosa layer may be explained by the fact that the thylakoids seems to bind to the mucosa layer as shown by
FIG. 4 . A visual inspection of the mucosa layer seems to confirm this. It is hypothesized that this binding may form a thylakoid layer acting as a barrier on the surface of the mucosa. This barrier may constitute a sterical hindrance bale to retard the passage of molecules, both small and large, through the mucosa as shown byFIGS. 1 to 3 . - Thylakoid membranes were prepared as described in EXAMPLE 1. Rats were of the Sprague-Dawley stock (Mole: SPRD Han).
- A rat was fed an emulsion of 2.5 g rapeseed oil in 5 g water (control) and a second rat was fed an emulsion of 2.5 g rapeseed oil in 5 g water plus 2.5 g thylakoids via bolustube. After 2.5 hours both rats were fed each 3 mL 15% glucose solution. Blood glucose was then measured at different times during 2 hours. The results are shown in Table 1 and
FIG. 5 . As can be seen there is a significant reduction of the blood glucose over time when thylakoids are co-administered. - An oil-in-water emulsion is advantageous, since it reduces the rate, with which thylakoids are digested by the body.
-
TABLE 1 Blood glucose concentration (mmol/L) at different times (min) after consumption of glucose with (Thylakoids) or without (Control) thykalkoids in the food. Time Control Thylakoids 0 7.15 5.2 15 11.35 6.2 30 11.55 7.4 45 8.6 7.8 60 9.49 9.4 -
- 1. Andreasson, E., Svensson, P. & Weibull, C. & Albertsson, P. A. (1988) Separation and characterization of stroma and grana membranes—evidence for heterogeneity in antenna size of both Photosystem I and Photosystem II. Biochimica et Biophysica Acta. 936, 339-350.
- 2. Emek, S. C., Szilagyi, A., Akerlund, H. E., Albertsson, P. A., Köhnke, R., Holm, A. & Erlanson-Albertsson, C. (2010) A large scale method for preparation of plant thylakoids for use in body weight regulation. Prep. Biochem. Biotechnol. 40, 13-27.
- 3. Ussing H H, Zerahn K (1951) Active transport of sodium as the source of electric current in the short-circuited isolated frog skin. Acta Physiol. Scand. 23, 110-127.
- 4. Grass G, Sweetana S (1988) In vitro measurement of gastrointestinal tissue permeability using a new diffusion cell. Pharm. Res. 5, 372-376.
- 5. Flores S, Graan T, Ort D R (1983) Measurement of the permeability of the chloroplast thylakoid membrane to amine buffers. Photobiochem. Photobiophys. 6, 293-304
- 6. Pantzar N, Westrom B R, Luts A et al. (1993) Regional Small-Intestinal Permeability in Vitro to Different-Sized Dextrans and Proteins in the Rat. Scand. J. Gastroenterol. 28, 205-211.
Claims (35)
1. A method of reducing and/or delaying the transport of glucose molecules through the intestinal tract of a mammal comprising administering to said mammal an effective amount of a composition comprising thylakoids, or parts thereof, enriched from green leaves or green algae, wherein said administration is to the intestinal tract of a mammal.
2. (canceled)
3. (canceled)
4. The method according to claim 1 , wherein hyperglycemia is prevented by said reducing and/or delaying the transport of glucose through the intestinal mucosa of the intestinal tract of a mammal.
5-7. (canceled)
8. The method according to claim 1 , wherein the thylakoids are concentrated so that the chlorophyll content is from about 8 mg to 80 mg chlorophyll per g composition (dry weight).
9. The method according to claim 1 , wherein the composition is provided so that the dose of thylakoids is 2.4 mg to 24 mg thylakoids per kg body mass of the mammal
10. (canceled)
11. (canceled)
12. (canceled)
13. (canceled)
14. The method claim 1 , wherein said composition is administered orally.
15. The method claim 1 , wherein said composition is part of a foodstuff or a medicament.
16. The method claim 1 , wherein said thylakoids, or parts thereof, are enriched from spinach.
17. The method according to claim 1 , wherein the composition is an oral pharmaceutical or nutraceutical composition comprising a physiologically tolerable oil-in-water emulsion comprising thylakoids.
18. The method according to claim 17 , wherein said composition comprises 25% (weight) thylakoids and about 25% (weight) oil.
19. (canceled)
20. The method claim 17 , wherein the transport of glucose through the intestinal mucosa of the intestinal tract of a mammal is reduced and/or delayed to treat a condition related to blood glucose levels by oral administration of the composition.
21. The method claim 17 , wherein the transport of glucose through the intestinal mucosa of the intestinal tract of a mammal is reduced and/or delayed to promote healthy blood sugar, to manage blood sugar levels, to support healthy blood sugar regulation, to enhance glucose metabolism, to improve blood glucose regulation, to improve pancreatic health, and combinations thereof.
22. (canceled)
23. A method of reducing the glycemic index of an initial foodstuff, comprising the step of adding a composition comprising thylakoids, or parts thereof, enriched from green leaves or green algae to the initial foodstuff to provide a modified foodstuff so that the glycemic index of the modified foodstuff is reduced as compared to the initial foodstuff when ingested by a mammal.
24. (canceled)
25. (canceled)
26. The method according to claim 23 , wherein in the composition comprising the thylakoids are concentrated so that the chlorophyll content is from about 8 mg to 80 mg chlorophyll per g composition (dry weight).
27. The method according to claim 23 , wherein said thylakoids, or parts thereof, are enriched from spinach.
28. The method according to claim 23 , wherein the composition is an oral nutraceutical composition comprising a physiologically tolerable oil-in-water emulsion comprising thylakoids.
29. The method according to claim 28 , wherein said composition further comprises 25% (weight) thylakoids and 25% (weight) oil.
30. A method of promoting healthy blood sugar, managing blood sugar levels, supporting healthy blood sugar regulation, enhancing glucose metabolism, improving blood glucose regulation, and/or improving pancreatic health in a subject comprising administering to said subject an effective amount of a concentrated thylakoid composition comprising from about 8 mg to 80 mg chlorophyll per g composition (dry weight).
31. The method of claim 30 , wherein said effective amount of said concentrated thylakoid composition reduces and/or delays the transport of glucose molecules through the intestinal tract of a mammal.
32. The method according to claim 30 , wherein the composition is provided so that the dose of thylakoids is 2.4 mg to 24 mg thylakoids per kg body mass of the mammal.
33. The method according to 30, wherein said composition is administered orally.
34. The method according to claim 30 , wherein said composition is part of a foodstuff or a medicament.
35. The method according to claim 30 , wherein said thylakoids, or parts thereof, are enriched from spinach.
36. The method according to claim 30 , wherein the composition is an oral pharmaceutical or nutraceutical composition comprising a physiologically tolerable oil-in-water emulsion comprising thylakoids.
37. The method according to claim 36 , wherein said composition further comprises 25% (weight) thylakoids and about 25% (weight) oil.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1150176 | 2011-02-25 | ||
SE1150176-4 | 2011-02-25 | ||
PCT/EP2012/053181 WO2012113918A1 (en) | 2011-02-25 | 2012-02-24 | Composition comprising thylakoids for delaying the uptake of molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
US20140037774A1 true US20140037774A1 (en) | 2014-02-06 |
Family
ID=45808809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/001,280 Abandoned US20140037774A1 (en) | 2011-02-25 | 2012-02-24 | Composition comprising thylakoids for delaying the uptake of molecules |
Country Status (4)
Country | Link |
---|---|
US (1) | US20140037774A1 (en) |
EP (1) | EP2678003A1 (en) |
CN (1) | CN103491947A (en) |
WO (1) | WO2012113918A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO2895012T3 (en) * | 2012-09-11 | 2018-03-17 | ||
CN106231923A (en) * | 2013-12-18 | 2016-12-14 | 斯拉毕思科股份公司 | Thylakoid reduces the purposes to dainty desire |
CN106456692A (en) | 2014-04-13 | 2017-02-22 | 马尔玛投资有限公司 | Dietary compositions for reducing blood glucose levels and for weight management |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101193649B (en) * | 2005-06-10 | 2014-06-11 | 斯拉毕思科股份公司 | Use of plant cell membrane for the for the treatment of obesity |
CN105267260A (en) * | 2008-07-14 | 2016-01-27 | 斯拉毕思科股份公司 | Large-scale process for the preparation of thylakoids |
-
2012
- 2012-02-24 CN CN201280019662.2A patent/CN103491947A/en active Pending
- 2012-02-24 US US14/001,280 patent/US20140037774A1/en not_active Abandoned
- 2012-02-24 EP EP12707070.4A patent/EP2678003A1/en not_active Withdrawn
- 2012-02-24 WO PCT/EP2012/053181 patent/WO2012113918A1/en active Application Filing
Non-Patent Citations (2)
Title |
---|
Kohknke et al. "Thylakoids promote release of the satiety hormone cholecystokinin while reducing insulin in healthy humans", (Scandinavian Journal of Gastroenterology, 2009, 1-8, iFirst article, pages 1-8) * |
Rayner et al. "Chloroplast thylakoid membrane-stabilized emulsions", (Journal of Science Food Agriculture, 2011 January 30;91(2): 315-21). * |
Also Published As
Publication number | Publication date |
---|---|
WO2012113918A1 (en) | 2012-08-30 |
EP2678003A1 (en) | 2014-01-01 |
CN103491947A (en) | 2014-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hossain et al. | Rare sugar D-allulose: Potential role and therapeutic monitoring in maintaining obesity and type 2 diabetes mellitus | |
Sophia et al. | Hypolipidemic activities of Ficus racemosa Linn. bark in alloxan induced diabetic rats | |
CN105394748A (en) | Method and composition for nutritionally improving glucose control and insulin action | |
Basha et al. | In vitro antidiabetic activity of Psidium guajava leaves extracts | |
KR101089957B1 (en) | Composition comprising arabinose from arabinoxylan for prevention and treatment of ischemic diseases and degenerative brain diseases | |
JP5658479B2 (en) | Composition showing activity such as fat reduction | |
JP5758561B2 (en) | Anti-obesity agent | |
US20140037774A1 (en) | Composition comprising thylakoids for delaying the uptake of molecules | |
CA3022247C (en) | Composition for treating diabetic disease | |
CN102844042A (en) | Novel use of polygonatum falcatum or polygonatum sibiricum extract | |
Tong et al. | Peptides derived from rice α-globulin reduce atherosclerosis in apolipoprotein E-deficient mice by inhibiting TNF-α-induced vascular endothelial cells injury | |
JP7294602B2 (en) | Composition for prevention or treatment of fatty liver disease | |
EP2323682B1 (en) | Compositions comprisng zinc-charged protein for increasing serum antioxidant concentrations | |
US20100297267A1 (en) | Compositions for diabetes treatment and prophylaxis | |
KR101999383B1 (en) | Pharmaceutical Composition for Improving, Protecting or Treating Alcoholic Liver Disease comprising Capsosiphon fulvescens Extract as Active Ingredient | |
Aizman et al. | The mechanisms of Curcuma longa rhizome action on glucose metabolism in alloxan–induced diabetic rats | |
KR101062003B1 (en) | Composition for the prevention and the treament of diabetes containing Alnus firma Sieb. et Zucc extracts or compounds separated therefrom as an effective ingredient | |
US9487596B2 (en) | Compound isolated from quamoclit, and composition for preventing or treating diabetes containing the compound as an active ingredient | |
KR20130075086A (en) | Composition for preventing or treating diabetes or diabetic complications | |
Prasetyo et al. | Antidiabetic and pancreato-protective effect of clove leaf essential oil in diabetic rats: in vivo and silico study | |
Munna | Pharmacological Evaluation of Methanolic Extract of Nigella sativa on Hyperglycemia in Laboratory Animal Models | |
KR20130009506A (en) | Cucurbitane and bitter gourd extracts for enhancing exercise performance and suppressing fatigue, and a composition containing the same | |
Joanta et al. | Hippophaea Rhamnoides Interferes With Insulin Release Via L-Type Ca 2+ Channel-Mediated Pathway In Rat Islet B-Cells. | |
JP2010512345A (en) | Extract from fruit skin of genusvitis plant, composition containing the same and method for producing the same | |
JP2008105982A (en) | Composition for prevention and treatment of diabetic disease and functional food for prevention and amelioration of diabetic disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: THYLABISCO AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ERLANSON ALBERTSSON, CHARLOTTE;ALBERTSSON, PER-AKE;REEL/FRAME:031444/0531 Effective date: 20131014 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |